Metagenomi Inc
Research Metagenomi Inc (MGX) on Bullrun: market cap USD 38.53M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMGX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 38.53M
- Financial periodQ2 2026
- Revenue-USD 257.00K
- Net income-USD 27.48M
- Free cash flow-USD 19.64M
Valuation Snapshot
latest market cap is USD 38.53M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 25.21M | -USD 87.87M | -USD 89.47M | n/a | -2.36 | USD 41.72M | USD 40.66M | USD 158.60M |
| FY2024 | USD 52.30M | -USD 78.06M | -USD 112.19M | n/a | -2.36 | USD 27.39M | USD 45.78M | USD 234.86M |
| FY2023 | USD 44.76M | -USD 68.26M | -USD 101.22M | n/a | -20.05 | USD 140.60M | USD 48.23M | -USD 135.58M |
| FY2022 | USD 17.20M | -USD 43.59M | USD 15.75M | n/a | -1.45 | USD 184.44M | USD 18.57M | -USD 74.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 38.53M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 60.95M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 135.08M | n/a | n/a | n/a |
About Metagenomi Inc
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Metagenomi Inc's market cap?
Metagenomi Inc's market capitalization is USD 38.53M.
What does Metagenomi Inc do?
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs.